Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.29 Consensus Target Price from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given an average recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $9.00.

A number of research analysts have recently weighed in on TSHA shares. Wells Fargo & Company raised their target price on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Needham & Company LLC raised their target price on Taysha Gene Therapies from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Saturday, September 27th. Bank of America assumed coverage on Taysha Gene Therapies in a report on Friday, July 11th. They set a “buy” rating and a $8.00 price target on the stock. Finally, Chardan Capital lifted their price target on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 12th.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total transaction of $646,000.00. Following the sale, the insider directly owned 1,006,439 shares in the company, valued at approximately $3,250,797.97. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds have recently bought and sold shares of the business. Jefferies Financial Group Inc. increased its position in Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock worth $23,825,000 after buying an additional 10,068,479 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Taysha Gene Therapies in the second quarter worth $11,178,000. MPM Bioimpact LLC purchased a new stake in Taysha Gene Therapies in the second quarter worth $6,823,000. Octagon Capital Advisors LP increased its position in Taysha Gene Therapies by 17.7% in the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after buying an additional 1,892,500 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Taysha Gene Therapies by 1,178.9% in the fourth quarter. Bank of America Corp DE now owns 1,710,303 shares of the company’s stock worth $2,959,000 after buying an additional 1,576,568 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Stock Down 2.5%

TSHA stock opened at $4.76 on Friday. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $5.40. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average is $3.03 and its 200-day moving average is $2.47. The firm has a market capitalization of $1.30 billion, a PE ratio of -14.00 and a beta of 0.99.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The company had revenue of $1.99 million during the quarter, compared to the consensus estimate of $1.61 million. Sell-side analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.